Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T 20G

Next Previous
Drug Profile

T 20G

Alternative Names: T-20 - Triastek; T-20G

Latest Information Update: 09 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Triastek
  • Class Antiarrhythmics; Antithrombotics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Atrial fibrillation; Venous thromboembolism

Most Recent Events

  • 27 Feb 2025 US FDA approves IND application for T20G
  • 16 Feb 2024 T 20 - Triastek is available for licensing as of 16 Feb 2024. https://www.triastek.com/partnering.html
  • 31 Jan 2024 Clinical trials in Atrial fibrillation in USA (PO) before January 2024 (Triastek pipeline, January 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top